Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction by Cleva, R.M et al.
394 Current  Neuropharmacology, 2010, 8, 394-408   
  1570-159X/10 $55.00+.00  ©2010 Bentham Science Publishers Ltd. 
Glutamatergic Targets for Enhancing Extinction Learning in Drug   
Addiction 
R.M. Cleva
1, J.T. Gass
1, J.J. Widholm
2 and M.F. Olive
1,3,* 
1Center for Drug and Alcohol Programs, Department of Psychiatry and Behavioral Sciences, Medical University   
of South Carolina, Charleston, South Carolina, 29425, USA; 
2Department of Psychology, College of Charleston, 
Charleston, South Carolina, 29424, USA; 
3Department of Neurosciences, Medical University of South Carolina, 
Charleston, South Carolina, 29425, USA 
Abstract: The persistence of the motivational salience of drug-related environmental cues and contexts is one of the most 
problematic obstacles to successful treatment of drug addiction. Behavioral approaches to extinguishing the salience   
of drug-associated cues, such as cue exposure therapy, have generally produced disappointing results which have been  
attributed to, among other things, the context specificity of extinction and inadequate consolidation of extinction learning. 
Extinction of any behavior or conditioned response is a process of new and active learning, and increasing evidence  
suggests that glutamatergic neurotransmission, a key component of the neural plasticity that underlies normal learning and 
memory, is also involved in extinction learning. This review will summarize findings from both animal and human studies 
that suggest that pharmacological enhancement of glutamatergic neurotransmission facilitates extinction learning in the 
context of drug addiction. Pharmacological agents that have shown potential efficacy include NMDA partial agonists, 
mGluR5 receptor positive allosteric modulators, inhibitors of the GlyT1 glycine transporter, AMPA receptor potentiators, 
and activators of the cystine-glutamate exchanger. These classes of cognition-enhancing compounds could potentially 
serve as novel pharmacological adjuncts to cue exposure therapy to increase success rates in attenuating cue-induced drug 
craving and relapse. 
Keywords: Extinction, learning, glutamate, NMDA, AMPA, mGluR5, GlyT1 glycine transporter, receptor potentiator,   
allosteric modulator, cystine-glutamate exchanger. 
INTRODUCTION 
  Drug addiction is a disorder of the nervous system char-
acterized by compulsive drug intake despite negative conse-
quences, numerous failed attempts at abstinence, and a   
narrowing of the behavioral repertoire towards drug-seeking 
and drug intake. Chronic, repeated drug use leads to the   
formation of powerful and lasting associations between the 
drug’s effects, drug-specific withdrawal symptoms, and the  
environmental cues and contexts that are present at the time 
these drug-related effects are experienced. As a result, these  
stimuli become overconditioned and overlearned [1], so that 
when experienced in the absence of the drug, they produce 
physiological responses (i.e., sympathetic nervous system 
activation) and maladaptive motivational states (i.e., drug 
craving). In other words, repeated drug intake causes drug-
associated external stimuli to become motivationally “hyper-
salient” and exert significant control over the addict’s behav-
ior [2, 3]. These drug-related stimuli are frequent triggers of 
drug craving, which leads to the resumption of drug-seeking 
behavior and ultimately relapse [2, 4-6]. Attempts at extin-
guishing the motivational salience of drug-associated cues 
and contexts by behavioral modification techniques such as 
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cue exposure therapy have been met with limited success [7-
9]. This general lack of success has been attributed to nu-
merous factors including the high degree of context specific-
ity of extinction [10-15] and inadequate consolidation of 
extinction learning [16]. Historically, most of what is known 
about the neural circuits and cellular and molecular mecha-
nisms underlying extinction learning has been derived from 
the study of extinction of conditioned fear [17]. However, 
there has been a recent resurgence of interest in understand-
ing the neural mechanisms underlying extinction of drug-
related cue reactivity, and pharmacologically targeting   
specific components of extinction learning to reduce the   
ability of drug-related cues and memories to elicit drug   
craving and relapse [16, 18, 19]. Current evidence, although 
limited, suggests that many of the neural mechanisms   
that underlie extinction of conditioned fear and that of drug-
related cue reactivity and drug-seeking behavior overlap to a 
significant degree [20]. 
  Since extinction is a process of active learning, it is not 
surprising that many of the key neural underpinnings of ex-
tinction learning are mediated by glutamatergic neurotrans-
mission, an established critical mediator of enduring changes 
in synaptic efficacy such as long-term potentiation (LTP) 
and long-term depression (LTD) that accompany learning 
[21-25]. It is therefore plausible to hypothesize that potentia-
tion of glutamate-mediated neural plasticity might enhance 
various forms of learning, including extinction learning. 
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meostasis is tightly regulated [26, 27], and overstimulation 
of which can lead to neuronal hyperexcitability and excito-
toxicity [27-29], pharmacological potentiation of glutama-
tergic transmission with the intent of enhancing extinction 
learning will therefore require subtle modulatory pharmacol-
ogical mechanisms of action rather than full glutamate recep-
tor agonism. 
  Following brief overviews of animal models of extinction 
of drug-seeking behavior, the neuroanatomical substrates of 
extinction, and glutamatergic synaptic transmission, the ma-
jority of this review will focus on pharmacological agents 
that enhance glutamate-mediated neurotransmission and 
have been shown to enhance extinction learning in animals 
as well as human in the context of the motivational salience 
of drug-related stimuli. The ultimate therapeutic goal of such 
pharmacological agents would be to serve as pharmacologi-
cal adjuncts to cue exposure therapy to improve the meager 
success rates currently achieved by this technique alone. 
While not the focus of this review, it is worth mentioning 
that drugs of abuse produce lasting changes in the brain, in-
cluding enduring synaptic plasticity [30-33], which have the 
net effect of tilting the motivation scale of addicts towards 
drug craving and drug-seeking behavior rather than absti-
nence or controlled drug intake. Therefore, therapeutic com-
pounds that enhance extinction learning via glutamatergic 
mechanisms are likely to be acting on receptor, transporter, 
or exchanger proteins whose expression levels, subcellular 
distribution, or posttranslational modifications have been 
altered by chronic drug exposure, which may in turn increase 
or decrease the efficacy of a particular compound. While 
there is some evidence that certain therapeutic agents such as 
D-cycloserine (see below) facilitate extinction learning in 
drug addicts and patients with anxiety disorders, it is possi-
ble that other classes of compounds discussed in this review 
may only enhance extinction learning in subpopulations of 
drug addicts or only those with pathological anxiety. 
  Finally, a discussion of the topic of extinction would be 
incomplete if a brief summary of the phenomenon of recon-
solidation were not provided. When the memory of a prior 
event is retrieved from long-term memory into working 
memory, the memory trace becomes labile, plastic, and sus-
ceptible to disruption or modification [34-37]. In order to 
maintain the memory trace, it must be reconsolidated back 
into long-term memory. The process of memory reconsolida-
tion involves many of the cellular and molecular processes 
that underlie initial memory formation, including glutama-
tergic signaling, de novo protein synthesis, expression of 
immediate early genes, and intracellular signaling pathways 
related to glutamatergic transmission [16, 38]. From a thera-
peutic perspective, it has been hypothesized that disruption 
of the reconsolidation of drug-related memories may reduce 
their motivational influence on drug craving and relapse   
[16, 18, 19]. However, agents that disrupt reconsolidation are 
amnestic in nature, whereas some of the pharmacological 
strategies to enhance glutamatergic signaling in order to fa-
cilitate extinction discussed in the present are pro-mnemonic 
in nature. Thus, disruption of reconsolidation and enhance-
ment of extinction learning represent two viable yet oppos-
ing strategies for reducing the influence of drug-associated 
stimuli and drug memories on drug-seeking and relapse. To 
underscore this point, Lee and colleagues [39] showed that 
infusions of the N-methyl-D-asparate (NMDA) glutamate 
receptor partial agonist D-cycloserine (DCS) into the baso-
lateral amygdala potentiated the reconsolidation of a co-
caine-related memory, where Botreau and colleagues [40] 
showed that the same manipulation facilitated the extinction 
of a cocaine conditioned place preference. Although these 
disparate results were likely a result of procedural differ-
ences in the timing of DCS administration (i.e., during the 
consolidation [40] or reconsolidation [39] time window), 
they highlight the importance of procedural variables, such 
as timing of drug administration during the targeted stage of 
learning and memory, that may be crucial determinants of 
the success of an amnestic or pro-mnemonic approach in 
decreasing the influence of drug-associated stimuli and drug 
memories on craving and relapse. 
ANIMAL MODELS OF EXTINCTION OF DRUG-
SEEKING BEHAVIOR 
  Cue exposure therapy in human drug addicts is designed 
to desensitize an individual’s conditioned physiological and 
psychological responses to drug-related stimuli as well as 
enhance cognitive and behavioral skills for coping with these 
responses. Early studies revealed that cue exposure therapy 
held significant potential for effective treatment of drug ad-
diction [41-44]. However, recent meta-analyses of the effec-
tiveness of cue exposure therapy for treatment of addiction 
have revealed that the success of this technique is only mod-
est at best [7-9]. The general lack of success of cue exposure 
therapy alone on drug-related cue reactivity and drug craving 
has been attributed to numerous factors, namely the high 
degree of context specificity of extinction learning [7, 8, 10-
12, 14, 15, 45] and inadequate consolidation of extinction 
learning [16]. While the context specificity of extinction 
learning can potentially be addressed by performing cue ex-
posure therapy in multiple contexts [46], some investigators 
have shown this approach to be disappointingly ineffective 
[47]. With regards to increasing the consolidation of extinc-
tion learning to improve the success of cue exposure therapy, 
we hypothesize that this effort can be approached pharmaco-
logically by modulating glutamatergic neurotransmission and 
using established animal models of addiction and extinction 
of drug-seeking behavior prior to moving the drug into clini-
cal trials. 
  Two of the most widely used animal models of drug ad-
diction are the conditioned place preference (CPP) and intra-
venous drug self-administration (IVSA) paradigm [48-52]. 
Both of these models are amenable to the study of extinction. 
In the CPP paradigm, an animal is passively administered a 
drug of abuse (such as cocaine) and then placed in a condi-
tioning compartment with unique tactile, visual, and/or olfac-
tory environmental cues for a set period of time. Drug condi-
tioning sessions are alternated with saline conditioning, 
whereby physiological saline is passively administered and 
the animal is placed in an adjacent compartment with tactile, 
visual, and/or olfactory cues that are distinct from the drug 
conditioning compartment. With repetition of these condi-
tioning procedures over a period of 1-2 weeks, the animal 
learns to associate the euphorigenic and physiological effects 
of the drug with the physical environment in which it is re-
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partments in a drug-free state, the animal will subsequently 
demonstrate an increased amount of time spent in the drug-
paired compartment as compared to time spent in the saline-
paired compartment (or as compared with the amount of time 
spent in the drug-paired compartment during a pre-test prior 
to drug conditioning). Extinction of an established CPP is 
accomplished either by repeatedly pairing the previously 
drug-paired compartment with saline, or by allowing   
the CPP to dissipate over a period of several weeks with   
repeated testing of place preference in the absence of further 
conditioning. 
  In the IVSA paradigm, an animal is trained to perform an 
operant response (such as pressing a lever) to obtain an infu-
sion of a drug solution through an indwelling intravenous 
catheter. Drug infusions are usually accompanied by discrete 
auditory and/or visual stimuli, which allows for associations 
between discrete environmental cues and drug infusions to 
be formed. Following the stabilization and maintenance of 
drug self-administration behavior for a period of time, the 
behavior can be subject to extinction by replacing the drug 
solution with saline, or by changing the outcome of the oper-
ant response so that it no longer has any programmed conse-
quences (i.e., drug infusion or cue presentation). During ex-
tinction training, new response-outcome contingencies are 
learned (i.e., the operant response no longer produces drug 
delivery), and since no drug reinforcer is delivered, a gradual 
decrease in operant responding is observed. Many research-
ers then proceed to administer a priming dose of the self-
administered drug, expose the animal to drug-associated 
cues, or introduce a mild stressor, all of which can result in a 
resumption of responding on the lever that previously deliv-
ered the drug infusion. This is referred to as “reinstatement” 
of drug-seeking behavior, and is an established model of 
relapse. The reinstatement model has been widely used to 
elucidate the neural substrates of relapse-like behaviors as 
well as assess the potential efficacy of pharmacological 
compounds or behavioral manipulations that might be devel-
oped as anti-relapse treatments [53, 54]. However, relatively 
little attention has been given to examining the neural   
circuitry and neuronal adaptations underlying extinction 
process in the CPP and IVSA paradigms, nor has there been 
much attention dedicated to the study of pharmacological 
enhancement of extinction learning. 
NEUROANATOMICAL BASIS OF EXTINCTION 
  As mentioned earlier, most of what is known about the 
neural substrates of extinction learning has been derived 
from the study of the extinction of conditioned fear. Intrac-
ranial neuronal recordings and microstimulation/microinjec- 
tion studies in rodents, as well as brain imaging studies in 
humans, have revealed that prefrontal cortex (PFC), hippo-
campus, and amygdala are involved in the extinction   
of conditioned fear [17, 55-61]. More specifically, electrical 
stimulation of the ventromedial PFC (vmPFC, which con-
tains the infralimbic cortex, ILC) in rodents facilitates the 
extinction of conditioned fear [62], and this region is acti-
vated when human subjects are exposed to fear-evoking 
stimuli following extinction of the fear response [59]. The 
vmPFC exerts inhibitory control over activity of the 
amygdala and its ability to generate fear responses [17]. Fear 
responses evoked by environmental contexts previously 
paired with noxious stimuli, as well as the extinction of these 
responses, are mediated by the hippocampus [63, 64]. Activ-
ity of the hippocampus is governed by numerous inputs in-
cluding reciprocal connections with both the vmPFC and 
amygdala. 
  Emerging evidence suggests a similar regulatory role of 
the vmPFC in the extinction of drug-seeking behavior and 
drug cue reactivity [20], and glutamatergic mechanisms have 
also been implicated. For example, Hsu and Packard showed 
that blockade of NMDA receptors in the PFC inhibited the 
extinction of an amphetamine CPP [65], whereas Peters and 
colleagues demonstrated that activation of the ILC by local 
infusion of AMPA blocked cocaine-induced reinstatement of 
extinguished cocaine-seeking behavior [66]. In contrast, in-
activation of the ILC actually induced the reinstatement of 
cocaine-seeking [66]. Similar observations were shown by 
Ovari and Leri, who demonstrated that inactivation of the 
vmPFC resulted in a re-emergence of a previously extin-
guished heroin CPP [67]. Since the vmPFC appears to have a 
facilitatory influence on extinction learning, it is possible 
that the dysfunction and underactivity of this and other re-
gions of the PFC that are often observed in long-term drug 
users [1, 68-73] limits the ability of the addict to extinguish 
his or her own drug-seeking behavior. 
  The amygdala, particularly the basolateral region (BLA), 
plays a role in the extinction of the salience of drug cues. 
The BLA is highly implicated in the formation of associa-
tions between drug and natural rewards and discrete envi-
ronmental cues [74-77], and exposure of current and former 
drug users to drug-related cues activates the amygdala [78-
84]. As will be discussed below, infusions of glutamatergic 
ligands into the BLA can alter extinction of conditioned fear-
related responses. It is also likely that the hippocampus is 
involved in the extinction of the salience of drug-related con-
textual cues, as inhibition of the dorsal hippocampus attenu-
ates context-induced reinstatement of cocaine-seeking be-
havior [85, 86], likely via interactions with the PFC and 
BLA [87]. Although these studies offer a rudimentary neural 
circuitry of addiction-related extinction learning, clearly 
more studies are warranted to more accurately define a com-
prehensive neural circuitry that underlies the extinction of 
drug-seeking behavior and the hypersalience of drug-related 
cues. 
THE GLUTAMATERGIC SYNAPSE 
  A diagram of a typical glutamatergic synapse is shown in 
Fig. (1). Following release into the synaptic cleft, glutamate 
can bind to one of three different types of ionotropic gluta-
mate receptors (iGluRs) located on the head of the postsyn-
aptic spine: the NMDA receptor, the -amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptor, and the 
kainic acid (kainate, KA) receptor. 
  NMDA receptors are heteromeric protein complexes that 
form ligand-gated ion channels composed of at least one 
NR1 subunit (for which there are at least 8 splice variants) 
and a combination of NR2A-D and NR3A or 3B subunits 
[88, 89]. In addition to being stimulated by glutamate,   
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co-agonists at the NMDA receptor. The NR2 subunit con-
tains the glutamate binding region, whereas the NR1 subunit 
contains the glycine-binding domain. Extracellular glycine 
levels are regulated by two subtypes of plasma membrane 
glycine transporters (designated GlyT1 and GlyT2). GlyT1 
was originally thought to be located only on glial cells [90-
91], but has recently been demonstrated to be found to be 
highly abundant at glutamatergic synapses, where it can be 
localized to postsynaptic membrane densities (see Fig. (1)) 
and physically interact with NMDA receptors [92]. NMDA 
receptors are primarily permeable to Ca
2+ ions upon activa-
tion, but certain subunit combinations allow for the influx  
of K
+ and Na
+ ions as well. The NMDA receptor has been 
extensively implicated in mediating neural plasticity as well 
as learning and memory processes [25, 93, 94]. 
  AMPA receptors are also heteromeric protein complexes 
that form ligand-gated ion channels. These receptors are 
composed of various subunits termed GluR1-4 (also termed 
GluRA-D) and GluR1 and 2 [95]. Once activated, AMPA 
receptors are permeable to various cations including Ca
2+, 
Na
+, and K
+, although the majority of AMPA receptors in the 
brain contain GluR2 subunits, which render the channel im-
permeable to Ca
2+. Both NMDA and AMPA receptors are 
necessary for the induction of many forms of synaptic plas-
ticity such as LTP and LTD [96-99]. 
  KA receptors (not shown in Fig. (1)) are ligand-gated ion 
channels composed of various subunits that can form ho-
momeric tetramers composed of GluR5, 6 or 7 subunits, or 
heteromeric complexes containing GluR5 or KA1 or 2 
subunits [95]. KA receptors are permeable to Na
+ and K
+ 
ions and, like NMDA and AMPA receptors, contribute to 
excitatory postsynaptic currents and synaptic plasticity [100, 
101]. Although a role for KA receptors in the reinstatement 
of drug-seeking behavior has been suggested [26], we know 
of no studies published to date implicating a role for these 
receptors in extinction learning. However, given their role in 
regulating synaptic plasticity, studies examining the role of 
KA receptor in extinction are clearly warranted. 
  In addition to iGluRs, glutamate can also bind to me-
tabotropic glutamate receptors (mGluRs), which are located 
either in the perisynaptic annulus or on presynaptic termi-
nals. mGluRs are seven transmembrane domain-containing 
G-protein coupled receptors (GPCRs) that mediate slower, 
modulatory glutamatergic transmission. mGluRs are typi-
cally divided into three distinct groups, based on their phar-
 
Fig. (1). The glutamatergic synapse and pharmacological targets for increasing synaptic plasticity and extinction learning. NMDA receptor 
function can by potentiated by activation of the glycine co-agonist binding site with the partial NMDA receptor agonist DCS or D-serine. 
Alternatively, NMDA receptor function can be also increased indirectly by inhibition of GlyT1 function, which elevates extracellular levels 
of the NMDA receptor co-agonist glycine, or by positive allosteric modulation of mGluR5, which indirectly increase NMDA receptor func-
tion. AMPA receptor activity can be enhanced with AMPA receptor potentiators. Finally, a nonspecific increase in extracellular glutamate 
can be obtained by stimulation of the glial cystine-glutamate exchanger (xc) with cystine derived from cystine prodrugs such as N-
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macological and signal transduction properties. Group I 
mGluR receptors (mGluR1 and mGluR5) activate the Gq 
class of G-proteins [102-104]. Group I mGluRs, particularly 
mGluR5, are positively coupled to NMDA receptor function 
(see Fig. (1)) [105-107], such that activation of mGluR5   
receptors increases NMDA-mediated excitatory postsynaptic 
activity. Group II (mGluR2 and mGluR3) and Group III 
(mGluR4, mGluR6, mGluR7, and mGluR8) mGluRs, acti-
vate the Gi class of G-proteins and are negatively coupled 
to adenylyl cyclase (AC) activity, 
  Activation of iGluRs alone is sufficient for the propaga-
tion of the action potential by the postsynaptic neuron, and 
can activate various intracellular signaling molecules includ-
ing protein kinase A (PKA), mitogen-activated protein 
kinase (MAPK), and extracellular signal-related kinase 
(ERK) [108] (see Fig. (1)). Activation of additional signaling 
molecules, such as protein kinase C (PKC) and release of 
Ca
2+ ions from intracellular stores, is achieved by activation 
of Group I mGluRs. Together, the simultaneous activation of 
iGluRs and mGluRs initiates a host of intracellular signaling 
cascades that result in phosphorylation of ligand- and volt-
age-gated ion channels, activation of other protein kinases 
and transcription factors, which eventually lead to the mo-
lecular events underlying hallmarks of neural plasticity such 
as LTP and LTD [21, 23, 109-111]. Such downstream events 
include initiation and/or regulation of dendritic mRNA trans-
lation and localized de novo protein synthesis, changes in 
gene expression in the nucleus, and cytoskeletal remodeling 
(see Fig. (1)). Glutamate-mediated neural plasticity is also 
characterized by changes in glutamate receptor trafficking 
such as insertion of AMPA receptors into postsynaptic 
plasma membrane [22]. 
  Extracellular glutamate levels are tightly regulated by a 
family of sodium-dependent excitatory amino acid transport-
ers (EAATs). To date, five separate EAATs have been iden-
tified, designated EAAT1-5. EAAT1-3 are alternatively 
termed glutamate aspartate transporter (GLAST), glutamate 
transporter 1 (GLT-1), and excitatory amino acid carrier 1 
(EAAC1), respectively, and are primarily (but not exclu-
sively) localized to glial cells [112-113], whereas EAAT4 is 
primarily localized to neurons and EAAT5 is primarily 
found in the retina [114]. This family of EAATs provides 
numerous mechanisms to prevent an excessive accumulation 
of extracellular glutamate, which if high enough concentra-
tions are reached, can result in excitotoxicity. Conversely, 
glutamate can be transported from within glial cells to the 
extracellular environment by the cystine-glutamate ex-
changer (xc) [115-118]. 
   It should be noted that, in support of the notion that glu-
tamatergic transmission is involved in extinction learning, 
animal studies have shown that extinction training following 
IVSA or CPP results in various neuroadaptive changes in 
numerous proteins found at glutamateric synapses. In the 
PFC, levels mRNA encoding the NR1 subunit of the NMDA 
receptor are initially elevated in the mPFC during the early 
phases of extinction, but later become decreased with   
extended extinction training [119]. Since NR1 subunits   
are present in all NMDA receptors, these findings suggest a 
general up-regulation of NMDA receptor expression occurs 
during the early phase of extinction, which may be a result of 
plastic events occurring during extinction learning. In   
the dorsal striatum and nucleus accumbens, which are   
dopaminergically innervated regions that are highly involved 
in mediating habit-learning, reward salience, and drug   
reinforcement, numerous extinction-induced neuroadaptive 
changes have been observed. Such changes include increases 
in levels of the NR1 subunit of the NMDA receptor [119-
121], the GluR1 and GluR2/3 subunits of the AMPA recep-
tor [120-122]. Conversely, extinction-induced reductions in 
expression of mGluR5 have been observed in these regions 
[123]. In the hippocampus, extinction of a morphine CPP 
results in an increase in phosphorylation of the serine 845 
residue of the GluR1 subunit of the AMPA receptor [124]. 
Such findings indicate that a significant degree of plasticity 
in glutamatergic synaptic components in various brain   
regions occurs as a result of extinction training, which   
lends further support to the notion that extinction is an active 
learning process involving glutamatergic transmission. 
GLUTAMATERGIC TARGETS FOR ENHANCING 
EXTINCTION LEARNING  
  Evidence reviewed so far that suggests that extinction of 
drug-seeking behavior and the hypersalience of drug-
associated stimuli is an active learning process, and that glu-
tamatergic transmission is a complex and critical mediator of 
synaptic plasticity and extinction learning. We therefore hy-
pothesize that pharmacological enhancement of glutamater-
gic transmission, via subtle modulatory mechanisms that do 
not result in excitotoxicity, may facilitate extinction learning 
in drug addiction. Pharmacological compounds that increase 
glutamatergic transmission, many of which are either ap-
proved for use in humans by regulatory agencies or are in 
clinical trials for the treatment of various neurological condi-
tions, may therefore serve as adjuncts to cue exposure ther-
apy. We will now review five different pharmacological 
classes of compounds by which glutamatergic transmission 
can be enhanced, and associated findings from human and 
animal studies that support the notion that such compounds 
may enhance extinction learning. This review will focus 
primarily on compounds that are systemically active, and   
the chemical structures of these compounds are shown in   
Fig. (2). It should be noted that various compounds in   
several of these classes are currently in active preclinical or 
clinical development, but their chemical structure has not yet 
been revealed and are thus not shown in Fig. (2). 
NMDA Receptor Partial Agonists 
   D-cycloserine (DCS, Fig. (2)) is a partial agonist at the 
N-methyl-D-aspartate (NMDA) glutamate receptor subtype 
that binds to the glycine co-agonist site located on the NR1 
subunit, which is present in all NMDA receptors in the cen-
tral nervous system. Numerous studies have shown that DCS 
facilitates the extinction of conditioned fear responses in 
animals and humans (see [125, 126] for reviews), and several 
recent animal studies have shown that DCS also facilitates 
the extinction of drug-seeking behavior. Botreau and col-
leagues [40] demonstrated in rats that had been administered 
cocaine (20 mg/kg i.p.) in the CPP paradigm, administration 
of DCS (15 mg/kg i.p.) immediately, but not 4 hours, follow-
ing CPP extinction tests facilitated the extinction of the   
cocaine CPP (i.e., DCS reduced the number of test sessions Glutamatergic Targets for Enhancing Extinction  Current Neuropharmacology, 2010, Vol. 8, No. 4    399 
required for the cocaine CPP to extinguish). The fact that the 
effects were observed when DCS was administered immedi-
ately following the extinction tests, and not 4 hours later, 
suggests that this compound facilitated the consolidation of 
extinction learning. These findings were independently repli-
cated in mice by Thanos and colleagues [127]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chemical structures of various systemically active pharmacological agents, categorized by mechanism of action, that may increase 
extinction learning via subtle enhancement of glutamatergic transmission. 
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  Botreau and colleagues [40] also demonstrated that infu-
sion of DCS directly into the BLA immediately following 
extinction sessions facilitated the extinction of a cocaine 
CPP. However, Lee and colleagues [39] found intra-BLA 
administration of DCS actually potentiated cue-induced rein-
statement of cocaine-seeking behavior. Although Botreau 
and colleagues did not examine reinstatement of CPP, their 
findings of facilitatory effects of DCS on extinction may 
seem contradictory to the potentiating effects of DCS on 
reinstatement as observed by Lee and colleagues. These ap-
parently discrepant findings are most likely attributable to 
the vastly different methodologies used in these studies. Bot-
reau and colleagues administered DCS into the BLA imme-
diately following extinction sessions in the CPP paradigm 
[40], while Lee and colleagues [39] employed an entirely 
different methodology. These investigators trained rats to 
intravenously self-administer cocaine for 10 days with stan-
dard response-contingent presentation of visual cues during 
drug infusions. Three days after the final self-administration 
session, animals were infused with DCS or vehicle into the 
BLA prior to a drug cue “reactivation” session, where ani-
mals were placed in the self-administration apparatus and 
exposed to 30 response-independent presentations of the 
cocaine-paired visual stimulus, which presumably reacti-
vated the cocaine-cue “memory”. Three days following this 
session, animals were tested for cue-induced reinstatement of 
drug-seeking behavior (i.e., resumption of lever pressing   
that resulted in drug cue presentation but no drug delivery). 
The results of this experiment showed a potentiation of cue-
induced reinstatement in animals receiving DCS into the 
BLA as compared with those receiving vehicle [39]. The 
authors attributed the ability of DCS to increase cue-induced 
cocaine-seeking to potentiation of the “reconsolidation”   
of the drug-cue memory. Thus, whether DCS facilitates   
the consolidation of extinction learning or promotes recon-
solidation of drug-related memories are highly dependent   
on the experimental procedures used and timing of DCS   
administration. 
  DCS (15 mg/kg i.p.) was also shown to facilitate the ex-
tinction of a cocaine CPP when extinction tests were per-
formed at intervals ranging from 3 to 14 days [128]. In addi-
tion, these investigators also demonstrated that acute admini-
stration of a priming dose of cocaine (5 mg/kg i.p.) did not 
reinstate cocaine CPP in animals treated with DCS during 
extinction, suggesting that increased consolidation of extinc-
tion learning may enable resistance to reinstatement and pos-
sibly reduce the incidence of relapse. However, Kelley and 
colleagues [129] found that DCS treatment failed to impair 
cocaine-primed reinstatement of a cocaine CPP. These dis-
crepant findings can again be explained by methodological 
differences between these two studies. In the study by Kelley 
and colleagues [129], DCS was administered prior to CPP 
extinction tests (which would affect the acquisition of extinc-
tion learning), whereas in the study by Paolone and col-
leagues [128] the drug was administered following extinction 
sessions, which would affect the consolidation of extinction 
learning. 
  With regards to other drugs of abuse, DCS (30 mg/kg 
i.p.) administered prior to extinction testing following place 
conditioning with ethanol (2 g/kg i.p.) in mice was shown to 
be ineffective in facilitating the extinction of an ethanol CPP 
[130]. Combined with the findings of Kelley et al. [129] 
mentioned above, these data suggest that DCS, when used in 
CPP paradigms, may be more effective in facilitating the 
consolidation of extinction learning rather than its acquisi-
tion. However, an operant self-administration study where 
discriminative stimuli (i.e., distinct olfactory scents) were 
used to allow the animals to predict the availability of oral 
ethanol or water [131] showed that pre-extinction session 
administration of DCS (5 mg/kg i.p.) facilitated the extinc-
tion of lever pressing for alcohol but not water when the re-
inforcer was withheld. DCS treatment also reduced the mag-
nitude of reinstatement of alcohol-seeking behavior pro-
duced by the combined presentation of the alcohol-
associated discriminative stimulus and presentation of alco-
hol to serve a gustatory and olfactory cue. Finally, post-
extinction session administration of DCS (30 mg/kg i.p.) has 
been shown to facilitate the extinction of operant food-
seeking behavior in mice [132]. Thus, while DCS may selec-
tively facilitate the consolidation of contextual extinction 
learning in CPP paradigms, there is evidence that DCS may 
facilitate both the acquisition and consolidation of instru-
mental extinction learning. Clearly more research in this   
area is needed to identify the ideal time points at which   
DCS administration produces the most robust facilitation of 
extinction learning. 
  In addition to facilitating the appetitive salience of   
drug-associated cues, DCS also facilitates the extinction   
of the conditioned aversive effects of drugs, such as drug   
withdrawal symptoms. It was recently demonstrated that 
administration of DCS (15 mg/kg i.p.) prior to naloxone-
precipitated morphine withdrawal in morphine-dependent 
rats facilitated the extinction of a resulting conditioned place 
aversion [133]. While additional studies are needed to con-
firm that DCS facilitates the extinction of the conditioned 
aversive properties of abstinence-induced drug withdrawal, 
which is more akin to drug withdrawal experienced by   
human addicts, these findings are encouraging as they   
demonstrate that DCS can facilitate both appetitive and   
aversive conditioned effects of drugs of abuse. This is   
especially important in light of the fact that drug use in   
humans is motivated by negative reinforcement processes 
that alleviate both conditioned and unconditioned drug   
withdrawal symptoms [134]. 
  While all of the aforementioned studies have been per-
formed in rodents, there is recent evidence to suggest that 
DCS may not facilitate extinction in all species. A recently 
published study showed that, as expected, pre-extinction 
session administration of DCS (30 mg/kg) facilitated the 
extinction of operant responding for a cocaine-paired lever in 
rats, but had no effect no effect in monkeys [135]. Nonethe-
less, this pre-extinction administration of DCS was effective 
in reducing the reacquisition of cocaine self-administration 
in both species. These results suggest that relapse-related 
behaviors may be altered by therapeutic drug treatment dur-
ing extinction despite a lack of observable effects during the 
extinction phase. 
  Similar to its cyclic analogue DCS, the endogenous 
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been shown to affect extinction responding following drug 
self-administration. In rats with a history of intravenous co-
caine self-administration, administration of D-serine at a 
dose of 100 mg/kg i.p. several hours prior to extinction train-
ing sessions facilitated the extinction of responding on the 
lever that previously delivered cocaine, but had no effect on 
the ability of a cocaine-associated cue to reinstate lever 
pressing [136]. This same group of investigators subse-
quently showed that the same dose of D-serine administered 
before or after extinction training in animals with a history of 
cocaine self-administration had no effect on responding dur-
ing the first day of extinction (although only a single 90-
minute extinction training session was allowed), but reduced 
the magnitude of reinstatement of responding induced by a 
priming dose of cocaine (0.5 mg/kg i.v.) [137]. Interestingly, 
these effects were not observed in animals that underwent 
one day of abstinence (i.e., no extinction training), suggest-
ing an interaction between the experience of extinction train-
ing and the ability of D-serine to attenuate the reinstatement 
of cocaine-seeking behavior. 
  Only two reports to date have been published on the ef-
fectiveness of DCS in reducing reactivity to drug-associated 
cues in humans. In a study by Santa Ana and colleagues 
[138], 25 cigarette smokers were administered either placebo 
(n=13) or DCS (n=12, 50 mg orally) 1 hour prior to two 
smoking-related cue exposure tests. It was found that partici-
pants receiving DCS demonstrated significant reductions in 
physiological arousal (as measured by skin conductance) in 
response to presentation of smoking-related cues, as well as 
reductions in self-reported urges to smoke as compared with 
participants that received placebo. These encouraging pre-
liminary findings suggest that DCS may be an effective ad-
junct to cue exposure therapy in facilitating extinction of 
conditioned responses to smoking-associated cues. However, 
another recent preliminary study conducted by Price and 
colleagues on the effects of DCS on cue reactivity in cocaine 
addicts found opposing results [139]. DCS (50 mg orally) or 
placebo (n=5 subjects per group) was administered 2 hours 
prior to cocaine-related cue reactivity tests. Surprisingly, 
subjects receiving DCS reported higher subjective ratings   
of cocaine craving during the first but not the second cue 
exposure test session. However, these preliminary results 
should be interpreted with caution, as only 5 subjects per 
group were used, yielding a statistical power value of 0.49, 
well below the standard accepted value of 0.80. In addition, 
statistical analysis of craving measures revealed only trends 
towards statistical significance, with p-values ranging from 
0.06 to 0.10. Finally, in the Santa Ana study [138], smokers 
were required to refrain from smoking overnight prior to   
cue testing, whereas in the study by Price and co-workers, 
cocaine addicts who were also cigarette smokers were given 
nicotine patches to prevent nicotine craving, and the pres-
ence of nicotine in the bloodstream may have altered the 
subjective reports of cocaine craving. Clearly, more studies 
on the effects of DCS on cue reactivity with large sample 
sizes, subjects addicted to other drugs of abuse, different 
timings of DCS administration, and the use of more than two 
cue exposure sessions to allow a greater degree of extinction 
learning to occur, are needed to determine the effectiveness 
of DCS in reducing cue reactivity in drug addicts. 
mGluR5 Positive Allosteric Modulators 
  While DCS and D-serine are direct partial agonists at the 
glycine binding site of the NMDA receptor, an alternative 
approach to increasing NMDA receptor function is by posi-
tive allosteric modulation of mGluR5 receptors. As shown in 
Fig. (1), these receptors are primarily located on the perisyn-
aptic annulus of postsynaptic dendritic spines. mGluR5 re-
ceptors are positively coupled to NMDA receptor function, 
such that potentiation of mGluR5 function increases NMDA 
receptor-mediated postsynaptic currents. mGluR5 receptors 
are highly expressed in forebrain regions such as the frontal 
cortex, olfactory bulb, dorsal and ventral striatum, amygdala, 
and hippocampus [140]. These receptors are known to be 
critically involved in drug reward and reinforcement [141-
146], synaptic plasticity [21, 23, 109-111], and learning and 
memory [147]. A role for mGluR5 receptors in extinction 
learning was recently demonstrated by Xu and colleagues 
[148], who demonstrated that mice lacking functional 
mGluR5 receptors failed to show evidence of extinction of 
contextual or cue conditioned fear. Thus, it is plausible (and 
now documented in the literature) that potentiation of 
mGluR5 function might actually enhance learning in certain 
paradigms, including extinction learning, as described below. 
  Positive allosteric modulators (PAMs) of mGluR5 recep-
tor function were originally designed to indirectly increase 
NMDA receptor function, and therefore possibly alleviate 
some of the cognitive deficits associated with schizophrenia 
in accordance with the NMDA receptor hypofunction model 
of this disorder [105-107, 149-151]. The development of 
mGluR5 PAMs was deemed to be advantageous over devel-
oping direct orthosteric agonists of the receptor for numerous 
reasons, including the poor selectivity offered by orthosteric 
agonists due to the high degree of homology of the glutamate 
binding site of the receptor across mGluR subtypes, poor 
brain penetrance of mGluR5 orthosteric agonists, and exces-
sive receptor stimulation which causes rapid receptor desen-
sitization. To circumvent these issues, mGluR5 PAMs were 
developed, which bind to the receptor at a site that is distinct 
from the orthosteric glutamate binding site and increase the 
functioning of the receptor upon the binding of endogenous 
glutamate. The first mGluR5 PAMs to be developed   
were (1E,2E)-1,2-bis(3-fluorobenzylidene)hydrazine (DFB) 
[152] and N-{5-chloro-2-[(-1,3-dioxoisoindolin-2-yl)methyl] 
phenyl}-2-hydroxybenzamide (CPPHA) [153, 154]. Another 
mGluR5 PAM that has been developed is 4-nitro-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide (VU-29) [155], and it 
was recently demonstrated that this compound enhances LTP 
and LTD in the hippocampal CA1 region in vitro [156], sug-
gesting that it may have cognition-enhancing properties. Un-
fortunately, these compounds exhibit poor brain penetrance 
which make them unsuitable for behavioral studies. None-
theless, one study did demonstrate that intracerebroventricu-
lar infusion of DFB in rats improved performance in a spatial 
alternation task [157]. 
  The first report of a systemically active mGluR5   
PAM was published by Lindsley and colleagues [158], who  
characterized the compound 3-cyano-N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamide (CDPPB, see Fig. (2)), which dis-
played antipsychotic-like properties [159-160]. Another sys-
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(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl} metha-
none (ADX47273, see Fig. (2)), was also characterized and 
demonstrated to have antipsychotic-like properties as well 
[161-162]. Interestingly, however, in normal unimpaired 
rodents, both CDPPB and ADX47273 administered s.c. or i.p. 
have been shown to have pro-cognitive and pro-mnemonic 
effects in behavioral tasks such as the novel object recogni- 
tion task [161, 163], the five-choice serial reaction time test 
[161], and the Morris water maze [156].  
  Given the pro-cognitive and pro-mnemonic effects of 
CDPPB, the effects of this compound on extinction learning 
have recently been explored. It has been found that CDPPB 
(3-30 mg/kg s.c.) administered prior to extinction sessions 
facilitated the extinction of a previously established cocaine 
CPP [164], and these effects were blocked by the mGluR5 
receptor antagonist 3-((2-methyl-4-thiazolyl)ethynyl)pyridine 
(MTEP) as well as an NMDA antagonist MK-801. Other 
studies show that CDPPB reduces extinction responding in 
rats with a history of intravenous cocaine or heroin self-
administration [165]. Despite its ability to indirectly enhance 
NMDA receptor function, repeated administration of CDPPB 
(30 mg/kg s.c.) did not produce evidence of neurotoxicity 
[164]. Although mGluR5 PAMs are primarily being devel-
oped for the treatment of schizophrenia, these data suggest 
that mGluR5 PAMs may also be useful in facilitating   
the extinction of drug-seeking behavior. It remains to be de-
termined if they also facilitate the extinction of drug-related 
cue reactivity. 
Glycine Transporter Inhibitors 
  Another method for indirectly potentiating NMDA recep-
tor function, and in turn enhancing synaptic plasticity and 
potentially facilitating extinction learning, is by inhibition of 
the activity of plasma membrane glycine transporters 
(GlyTs, with subtypes designated GlyT1 and GlyT2) [166-
169]. These transporters, particularly the GlyT1 subtype, 
locally regulate extracellular levels of the endogenous 
NMDA receptor co-agonist glycine [170]. Early in situ  
hybridization and immunohistochemistry studies showed 
that GlyT1 transporters were primarily localized to glial   
cells [90, 91], but more recently it has been demonstrated by 
electron microscopy with improved antisera against GlyT1 
that these transporters are highly concentrated at glutamatergic 
synapses on both the pre- and postsynaptic membranes,   
and physically interact with postsynaptic NMDA receptors 
[92]. GlyT1 transporters are widely expressed throughout   
the brain, although there is some regional variation in levels 
of protein expression, whereas GlyT2 tranporter expression 
is primarily confined to the spinal cord, brainstem, and   
cerebellum, where it is found on presynaptic terminals and 
glial cells. 
  One of the first systemically active and selective GlyT1 
inhibitors to be characterized was N-[3-([1,1-biphenyl]-4-
yloxy)-3-(4-fluorophenyl)propyl]sarcosine (NFPS, also 
known as ALX 5407) [171]. Many other selective and brain 
penetrant GlyT1 inhibitors have since been synthesized   
and characterized, including cis-N-methyl-N-(6-methoxy-1-
phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethyl 
carboxylic acid hydrochloride (Org 25935) [172], 2-chloro-
N-[1-(ethylsulfonyl)-4-isobutylpiperidin-4-yl]methyl)}-4-(tri-
fluoromethyl)benzamide (Compound 5) [173, 174], [2-(4-
benzo[1,3]dioxol-5-yl-2-tert-butylphenoxy)ethyl]-methyl- 
amino}-acetic acid (LY2365109) [175], and 2-chloro-N-
[(S)-phenyl[(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl 
benzamide (SSR504734) [176]. The chemical structures of 
these compounds are shown in Fig. (2). 
  Inhibition of GlyT1 function by either pharmacological 
inhibition or targeted gene deletion has been shown to facili-
tate associative and spatial reversal learning, working and 
spatial memory, and object recognition memory [177-181]. 
Compound 5 has been shown to attenuate the ability of nico-
tine to reinstate sucrose-seeking [182], although the drug was 
given prior to reinstatement, and its effects on extinction 
learning were not determined in this study. To date only one 
study relevant to extinction has been published on GlyT1 
inhibitors and extinction. In this study, local delivery of 
NFPS into the amygdala of rats facilitated the extinction of 
conditioned fear [183], which raises the possibility that 
GlyT1 function may also facilitate extinction learning in the 
context of drug addiction. While to our knowledge no such 
studies have been published to date on effects of GlyT1 in-
hibitors in the context of drug addiction, such studies are 
clearly warranted based on the aforementioned results. 
AMPA Receptor Potentiators 
  Similar to NMDA receptors, AMPA receptors are criti-
cally involved in synaptic plasticity and learning and mem-
ory processes [21-25]. Substantial effort has been devoted to 
developing small molecule compounds that selectively in-
crease AMPA receptor function without inducing neuronal 
hyperexcitability or excitotoxicity. Such compounds have 
been termed “AMPAkines”, AMPA receptor potentiators, or 
AMPA receptor positive allosteric modulators. These com-
pounds facilitate LTP and improve performance in learning 
and memory tasks in rodents such as spatial navigation, odor 
discrimination, non-matching-to-sample short-term memory 
tests, and have yielded some positive results in psychological 
tests in humans [184, 185]. Numerous selective and systemi-
cally active AMPA receptor potentiators have been devel-
oped for potential use as cognition-enhancing agents in dis-
orders such as schizophrenia and Alzheimer’s disease, in-
cluding 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-
phenoxyacetamide (PEPA) [186], 6-(piperidin-1-ylcarbonyl) 
quinoxaline (CX-516) [187], 2,1,3-benzoxadiazol-6-yl-
piperidin-1-ylmethanone (CX-691, also known as Farampa-
tor or Org 24448) [188], and 7-chloro-3-methyl-3-4-dihydro-
2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA-21) [189]. 
Recent studies have demonstrated that PEPA facilitates the 
extinction of conditioned fear responses [190-191], and rele-
vant to addiction, LaLumiere and Kalivas recently demon-
strated that infusions of PEPA into the infralimbic region of 
the prefrontal cortex enhances the retention of extinction 
learning following cocaine self-administration [192]. Further 
support for an important role of AMPA receptors in extinc-
tion learning comes from a study by Sutton and colleagues, 
who showed that increasing AMPA receptor function by 
virally-induced overexpression of the GluR1 and GluR2 
subunits of the AMPA receptor in the nucleus accumbens 
facilitates the extinction of cocaine-seeking behavior [122]. 
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other possible pharmacological mechanism to facilitate   
extinction learning in addiction. 
Cystine-Glutamate Exchanger Activators 
  Extracellular levels of glutamate are tightly regulated by 
various transporter proteins, including neuronal and glial 
glutamate transporters (as discussed previously) and other 
proteins such as the cystine-glutamate exchanger (often ab-
breviated xc) located on glial cells (see Fig. (1)). The cystine 
prodrug N-acetylcysteine (NAC, see Fig. (2)) is converted to 
cysteine following penetration into the brain and ultimately 
to cystine, which stimulates xc. The resulting effect is an 
increase in extracellular glutamate levels that arises from 
cytoplasmic pools inside glial cells expressing xc. NAC is 
particularly effective in elevating extracellular glutamate 
levels when they are below normal, such as during cocaine 
withdrawal [117, 193]. NAC has been shown in rodents to 
normalize deficits in extracellular levels of glutamate in 
forebrain regions such as the nucleus accumbens during co-
caine withdrawal, and inhibit the ability of acute cocaine 
exposure to reinstate cocaine-seeking behavior [118, 193-
195]. NAC also reverses the metaplasticity (an alteration in 
the ability to induce LTP or LTD) in the nucleus accumbens 
following cocaine self-administration [195]. In contrast, 
pharmacological blockade of xc with (S)-4-carboxyphenyl- 
glycine (CPG) actually promotes cocaine-seeking behavior 
[196]. Recently, NAC has been tested in clinical trials in 
human addicts and has been shown to reduce cue reactivity 
and craving in cocaine addicts [197, 198] and reduce cigarette 
smoking [199]. 
    Since NAC nonspecifically enhances glutamatergic 
transmission by increasing extracellular levels of this excita-
tory amino acid, it can potentially activate numerous post-
synaptic glutamate receptors (i.e., AMPA, NMDA, mGluRs, 
etc.). It was recently demonstrated that the ability of NAC to 
restore LTP in the nucleus accumbens was due to actions of 
glutamate on presynaptic mGluR2/3 receptors, whereas the 
ability of NAC to restore LTD was due to stimulation of 
mGluR5 receptors [195], consistent with evidence that 
mGluR5 receptors mediate drug-induced alterations in syn-
aptic plasticity [146]. Although studies on the effects of 
NAC on enhancement on normal learning processes are lack-
ing, Zhou and Kalivas demonstrated that NAC reduced ex-
tinction responding following intravenous heroin self-
administration in rats [200], and produced lasting reductions 
in the reinstatement of heroin-seeking behavior. Similar in-
hibitory effects of NAC on extinction responding have re-
cently been reported in rats with a history of cocaine self-
administration [201]. Thus, NAC may be a novel potential 
adjunct to cue exposure therapy to facilitate the extinction of 
cue-evoked cocaine craving as well as reducing cocaine and 
heroin-seeking behavior. 
CONCLUSIONS 
  Drug-associated environmental stimuli induce drug crav-
ing, which in turn motivates drug-seeking behavior and often 
result in relapse. The combination of the prevalence of drug-
associated cues in the addict’s day-to-day life, the context-
specificity of extinction learning, and the enduring neu-
roadaptive changes in the brain produced by repeated drug 
use, create a substantial uphill battle in the development of 
successful treatments for drug addiction. As many common 
neural mechanisms underlie both normal learning and mem-
ory processes and drug addiction, targeting neural systems 
with either pro-cognitive or pro-mnemonic agents to facili-
tate extinction learning and improve cognitive abilities are 
potentially promising avenues for both basic and clinical 
research that may improve the long-term outcomes of the 
treatment of addiction [202]. We hypothesize that pharma-
cological agents that enhance glutamatergic transmission   
via subtle mechanisms, including NMDA receptor partial 
agonism, mGluR5 and AMPA receptor potentiation, GlyT1 
inhibition, and cystine-glutamate exchanger activation, may 
be of potential benefit in enhancing synaptic plasticity and 
thereby facilitating extinction learning. Undoubtedly such 
pharmacological approaches, if devoid of toxicological or 
adverse side effects and approved by appropriate regulatory 
agencies, will have to be correctly incorporated into cue   
exposure therapy practices and cognitive-behavioral therapy 
in order to maximize their effectiveness. 
ACKNOWLEDGEMENTS 
  RMC and MFO are supported by research grant 
DA024355 from the National Institute on Drug Abuse to 
MFO, JTG is supported by training grant AA007474 from 
the National Institute on Alcohol Abuse and Alcoholism, and 
JJW is supported by the College of Charleston. All authors 
have no conflicts of interest to declare. 
REFERENCES 
[1]  Redish, A.D.; Jensen, S.; Johnson, A. A unified framework for 
addiction: vulnerabilities in the decision process. Behav. Brain Sci., 
2008, 31, 415-437. 
[2]  O'Brien, C.P.; Childress, A.R.; Ehrman, R.; Robbins, S.J. 
Conditioning factors in drug abuse: can they explain compulsion? 
J. Psychopharmacol., 1998, 12, 15-22. 
[3]  O'Brien, C.; Childress, A.; McLellan, A.; Ehrman, R.; Ternes, J. 
Progress in understanding the conditioning aspects of drug 
dependence. NIDA Res. Monogr., 1988, 81, 395-404. 
[4]  Childress, A.R.; Hole, A.V.; Ehrman, R.N.; Robbins, S.J.; 
McLellan, A.T.; O'Brien, C.P. Cue reactivity and cue reactivity 
interventions in drug dependence. NIDA Res. Monogr., 1993, 137, 
73-95. 
[5]  Kalivas, P.W.; Volkow, N.D. The neural basis of addiction: a 
pathology of motivation and choice. Am. J. Psychiatry, 2005, 162, 
1403-1413. 
[6]  Childress, A.R.; McLellan, A.T.; O'Brien, C.P. Role of 
conditioning factors in the development of drug dependence. 
Psychiatr. Clin. North Am., 1986, 9, 413-425. 
[7]  Conklin, C.A.; Tiffany, S.T. Applying extinction research and 
theory to cue-exposure addiction treatments. Addiction, 2002, 97, 
155-167. 
[8]  Havermans, R.C.; Jansen, A.T. Increasing the efficacy of cue 
exposure treatment in preventing relapse of addictive behavior. 
Addict. Behav, 2003, 28, 989-994. 
[9]  Martin, T.; LaRowe, S.D.; Malcolm, R. Progress in cue extinction 
therapy for the treatment of addictive disorders: a review update. 
Open Addict. J., 2010, 3, 92-101. 
[10]  Bouton, M.E. Context, time, and memory retrieval in the 
interference paradigms of Pavlovian learning. Psychol. Bull., 1993, 
114, 80-99. 
[11]  Bouton, M.E. Context, ambiguity, and unlearning: sources of 
relapse after behavioral extinction. Biol. Psychiatry, 2002, 52, 976-
986. 
[12]  Bouton, M.E. Context and behavioral processes in extinction. 
Learn. Mem., 2004, 11, 485-494. 404    Current Neuropharmacology, 2010, Vol. 8, No. 4  Cleva et al. 
[13]  Bouton, M.E.; Swartzentruber, D. Sources of relapse after 
extinction in Pavlovian and instrumental learning. Clin. Psychol. 
Rev., 1991, 11, 123-140. 
[14]  Bouton, M.E.; Westbrook, R.F.; Corcoran, K.A.; Maren, S. 
Contextual and temporal modulation of extinction: behavioral and 
biological mechanisms. Biol. Psychiatry, 2006, 60, 352-360. 
[15]  Rescorla, R.A. Preservation of Pavlovian associations through 
extinction. Q. J. Exp. Psychol., 1996, 49B, 245-258. 
[16]  Taylor, J.R.; Olausson, P.; Quinn, J.J.; Torregrossa, M.M. 
Targeting extinction and reconsolidation mechanisms to combat the 
impact of drug cues on addiction. Neuropharmacology, 2009, 56 
(Suppl), 186-195. 
[17]  Delgado, M.R.; Nearing, K.I.; LeDoux, J.E.; Phelps, E.A. Neural 
circuitry underlying the regulation of conditioned fear and 
extinction. Neuron, 2008, 59, 829-838. 
[18]  Diergaarde, L.; Schoffelmeer, A.N.; De Vries, T.J. Pharmacolo- 
gical manipulation of memory reconsolidation: towards a novel 
treatment of pathogenic memories. Eur. J. Pharmacol., 2008, 585, 
453-457. 
[19]  Centonze, D.; Siracusano, A.; Calabresi, P.; Bernardi, G. Removing 
pathogenic memories: a neurobiology of psychotherapy. Mol. 
Neurobiol., 2005, 32, 123-132. 
[20]  Peters, J.; Kalivas, P.W.; Quirk, G.J. Extinction circuits for fear and 
addiction overlap in prefrontal cortex. Learn. Mem., 2009, 16, 279-
288. 
[21]  Reis, H.J.; Guatimosim, C.; Paquet, M.; Santos, M.; Ribeiro, F.M.; 
Kummer, A.; Schenatto, G.; Salgado, J.V.; Vieira, L.B.; Teixeira, 
A.L.; Palotas, A. Neuro-transmitters in the central nervous system 
& their implication in learning and memory processes. Curr. Med. 
Chem., 2009, 16, 796-840. 
[22]  Rao, V.R.; Finkbeiner, S. NMDA and AMPA receptors: old 
channels, new tricks. Trends Neurosci., 2007, 30, 284-291. 
[23]  Miyamoto, E. Molecular mechanism of neuronal plasticity: 
induction and maintenance of long-term potentiation in the 
hippocampus. J. Pharmacol. Sci., 2006, 100, 433-442. 
[24]  Robbins, T.W.; Murphy, E.R. Behavioural pharmacology: 40+ 
years of progress, with a focus on glutamate receptors and 
cognition. Trends Pharmacol. Sci., 2006, 27, 141-148. 
[25]  Riedel, G.; Platta, B.; Micheaub, J. Glutamate receptor function in 
learning and memory. Behav. Brain Res., 2003, 140, 1-47. 
[26]  Kalivas, P.W. The glutamate homeostasis hypothesis of addiction. 
Nat. Rev. Neurosci., 2009, 10, 561-572. 
[27]  Moulder, K.L.; Meeks, J.P.; Mennerick, S. Homeostatic regulation 
of glutamate release in response to depolarization. Mol. Neurobiol., 
2006, 33, 133-153. 
[28]  Dong, X.X.; Wang, Y.; Qin, Z.H. Molecular mechanisms of 
excitotoxicity and their relevance to pathogenesis of 
neurodegenerative diseases. Acta Pharmacol. Sin., 2009, 30, 379-
387. 
[29]  Choi, D.W. Excitotoxic cell death. J. Neurobiol., 1992, 23, 1261-
1276. 
[30]  Kauer, J.A. Learning mechanisms in addiction: synaptic plasticity 
in the ventral tegmental area as a result of exposure to drugs of 
abuse. Annu. Rev. Physiol., 2004, 66, 447-475. 
[31]  Kauer, J.A.; Malenka, R.C. Synaptic plasticity and addiction. Nat. 
Rev. Neurosci., 2007, 8, 844-858. 
[32]  Jones, S.; Bonci, A. Synaptic plasticity and drug addiction. Curr. 
Opin. Pharmacol., 2005, 5, 20-25. 
[33]  Kalivas, P.W.; O'Brien, C. Drug addiction as a pathology of   
staged neuroplasticity. Neuropsychopharmacol. Rev.,  2008,  33, 
166-180. 
[34]  Tronson, N.C.; Taylor, J.R. Molecular mechanisms of memory 
reconsolidation. Nat. Rev. Neurosci., 2007, 8, 262-275. 
[35]  Lee, J.L. Reconsolidation: maintaining memory relevance. Trends 
Neurosci., 2009, 32, 413-420. 
[36]  Moore, J.L.; Roche, R.A. Reconsolidation revisited: a review and 
commentary on the phenomenon. Rev. Neurosci., 2007, 18, 365-
382. 
[37]  Schiller, D.; Monfils, M.H.; Raio, C.M.; Johnson, D.C.; Ledoux, 
J.E.; Phelps, E.A. Preventing the return of fear in humans using 
reconsolidation update mechanisms. Nature, 2010, 463, 49-53. 
[38]  Milton, A.L.; Lee, J.L.; Butler, V.J.; Gardner, R.; Everitt, B.J. 
Intra-amygdala and systemic antagonism of NMDA receptors 
prevents the reconsolidation of drug-associated memory and 
impairs subsequently both novel and previously acquired drug-
seeking behaviors. J. Neurosci., 2008, 28, 8230-8237. 
[39]  Lee, J.L.; Gardner, R.J.; Butler, V.J.; Everitt, B.J. D-cycloserine 
potentiates the reconsolidation of cocaine-associated memories. 
Learn. Mem., 2009, 16, 82-85. 
[40]  Botreau, F.; Paolone, G.; Stewart, J. d-Cycloserine facilitates 
extinction of a cocaine-induced conditioned place preference. 
Behav. Brain Res., 2006, 172, 173-178. 
[41]  Hammersley, R. Cue exposure and learning theory. Addict. Behav., 
1992, 17, 297-300. 
[42]  Heather, N.; Bradley, B.P. Cue exposure as a practical treatment 
for addictive disorders: why are we waiting? Addict. Behav., 1990, 
15, 335-337. 
[43]  O'Brien, C.P.; Childress, A.R.; McLellan, T.; Ehrman, R. 
Integrating systemic cue exposure with standard treatment in 
recovering drug dependent patients. Addict. Behav., 1990, 15, 355-
365. 
[44]  Marlatt, G.A. Cue exposure and relapse prevention in the treatment 
of addictive behaviors. Addict. Behav., 1990, 15, 395-399. 
[45]  Tobena, A.; Fernandez-Teruel, A.; Escorihuela, R.M.; Nunez, J.F.; 
Zapata, A.; Ferre, P.; Sanchez, R. Limits of habituation and 
extinction: implications for relapse prevention programs in 
addictions. Drug Alcohol Depend., 1993, 32, 209-217. 
[46]  Stasiewicz, P.R.; Brandon, T.H.; Bradizza, C.M. Effects of 
extinction context and retrieval cues on renewal of alcohol-cue 
reactivity among alcohol-dependent outpatients. Psychol. Addict. 
Behav., 2007, 21, 244-248. 
[47]  MacKillop, J.; Lisman, S.A. Effects of a context shift and multiple 
context extinction on reactivity to alcohol cues. Exp. Clin. 
Psychopharmacol., 2008, 16, 322-331. 
[48]  Olmstead, M.C. Animal models of drug addiction: where do we go 
from here? Q. J. Exp. Psychol., 2006, 59, 625-653. 
[49]  Sanchis-Segura, C.; Spanagel, R. Behavioural assessment of drug 
reinforcement and addictive features in rodents: an overview. 
Addict. Biol., 2006, 11, 2-38. 
[50]  Panlilio, L.V.; Goldberg, S.R. Self-administration of drugs in 
animals and humans as a model and an investigative tool. 
Addiction, 2007, 102, 1863-1870. 
[51]  Gardner, E.L. Use of animal models to develop antiaddiction 
medications. Curr. Psychiatry Rep., 2008, 10, 377-384. 
[52]  O'Brien, C.P.; Gardner, E.L. Critical assessment of how to study 
addiction and its treatment: human and non-human animal models. 
Pharmacol. Ther., 2005, 108, 18-58. 
[53]  Epstein, D.H.; Preston, K.L. The reinstatement model and relapse 
prevention: a clinical perspective. Psychopharmacology (Berl), 
2003, 168, 31-41. 
[54]  Epstein, D.H.; Preston, K.L.; Stewart, J.; Shaham, Y. Toward a 
model of drug relapse: an assessment of the validity of the 
reinstatement procedure. Psychopharmacology (Berl),  2006,  189, 
1-16. 
[55]  Quirk, G.J.; Mueller, D. Neural mechanisms of extinction learning 
and retrieval. Neuropsychopharmacol. Rev., 2008, 33, 56-72. 
[56]  Quirk, G.J.; Garcia, R.; Gonzalez-Lima, F. Prefrontal mechanisms 
in extinction of conditioned fear. Biol. Psychiatry, 2006, 60, 337-
343. 
[57]  Likhtik, E.; Popa, D.; Apergis-Schoute, J.; Fidacaro, G.A.; Pare, D. 
Amygdala intercalated neurons are required for expression of fear 
extinction. Nature, 2008, 454, 642-645. 
[58]  Milad, M.R.; Quirk, G.J. Neurons in medial prefrontal cortex signal 
memory for fear extinction. Nature, 2002, 420, 70-74. 
[59]  Milad, M.R.; Wright, C.I.; Orr, S.P.; Pitman, R.K.; Quirk, G.J.; 
Rauch, S.L. Recall of fear extinction in humans activates the 
ventromedial prefrontal cortex and hippocampus in concert. Biol. 
Psychiatry, 2007, 62, 446-454. 
[60]  Barad, M.; Gean, P.W.; Lutz, B. The role of the amygdala in   
the extinction of conditioned fear. Biol. Psychiatry, 2006, 60, 322-
328. 
[61]  Sotres-Bayon, F.; Cain, C.K.; LeDoux, J.E. Brain mechanisms of 
fear extinction: historical perspectives on the contribution of 
prefrontal cortex. Biol. Psychiatry, 2006, 60, 329-336. 
[62]  Vidal-Gonzalez, I.; Vidal-Gonzalez, B.; Rauch, S.L.; Quirk, G.J. 
Microstimulation reveals opposing influences of prelimbic and 
infralimbic cortex on the expression of conditioned fear. Learn. 
Mem., 2006, 13, 728-733. Glutamatergic Targets for Enhancing Extinction  Current Neuropharmacology, 2010, Vol. 8, No. 4    405 
[63]  Corcoran, K.A.; Desmond, T.J.; Frey, K.A.; Maren, S. 
Hippocampal inactivation disrupts the acquisition and contextual 
encoding of fear extinction. J. Neurosci., 2005, 25, 8978-8987. 
[64]  Corcoran, K.A.; Maren, S. Hippocampal inactivation disrupts 
contextual retrieval of fear memory after extinction. J. Neurosci., 
2001, 21, 1720-1726. 
[65]  Hsu, E.; Packard, M.G. Medial prefrontal cortex infusions of 
bupivacaine or AP-5 block extinction of amphetamine conditioned 
place preference. Neurobiol. Learn. Mem., 2007, 89, 504-512. 
[66]  Peters, J.; Lalumiere, R.T.; Kalivas, P.W. Infralimbic prefrontal 
cortex is responsible for inhibiting cocaine seeking in extinguished 
rats. J. Neurosci., 2008, 28, 6046-6053. 
[67]  Ovari, J.; Leri, F. Inactivation of the ventromedial prefrontal cortex 
mimics re-emergence of heroin seeking caused by heroin 
reconditioning. Neurosci. Lett., 2008, 444, 52-55. 
[68]  Kalivas, P.W.; Volkow, N.; Seamans, J. Unmanageable motivation 
in addiction: a pathology in prefrontal-accumbens glutamate 
transmission. Neuron, 2005, 45, 647-650. 
[69]  Crews, F.T.; Boettiger, C.A. Impulsivity, frontal lobes and risk for 
addiction. Pharmacol. Biochem. Behav., 2009, 93, 237-247. 
[70]  Kalivas, P.W. Addiction as a pathology in prefrontal cortical 
regulation of corticostriatal habit circuitry. Neurotox. Res., 2008, 
14, 185-189. 
[71]  Volkow, N.D.; Fowler, J.S.; Wang, G.J.; Swanson, J.M.; Telang, F. 
Dopamine in drug abuse and addiction: results of imaging studies 
and treatment implications. Arch. Neurol., 2007, 64, 1575-1579. 
[72]  Everitt, B.J.; Hutcheson, D.M.; Ersche, K.D.; Pelloux, Y.; Dalley, 
J.W.; Robbins, T.W. The orbital prefrontal cortex and drug 
addiction in laboratory animals and humans. Ann. N. Y. Acad. Sci., 
2007, 1121, 576-597. 
[73]  Schoenbaum, G.; Shaham, Y. The role of orbitofrontal cortex in 
drug addiction: a review of preclinical studies. Biol. Psychiatry, 
2008, 63, 256-262. 
[74]  Everitt, B.J.; Morris, K.A.; O'Brien, A.; Robbins, T.W. The 
basolateral amygdala-ventral striatal system and conditioned place 
preference: further evidence of limbic-striatal interactions 
underlying reward-related processes. Neuroscience, 1991, 42, 1-18. 
[75]  Cardinal, R.N.; Parkinson, J.A.; Hall, J.; Everitt, B.J. Emotion and 
motivation: the role of the amygdala, ventral striatum and 
prefrontal cortex. Neurosci. Biobehav. Rev., 2002, 26, 321-352. 
[76]  Baxter, M.G.; Murray, E.A. The amygdala and reward. Nat. Rev. 
Neurosci., 2002, 3, 563-573. 
[77]  Olive, M.F. Role of the amygdala in drug-related memories. Cell 
Sci., 2009, 6, 87-103. 
[78]  Bonson, K.R.; Grant, S.J.; Contoreggi, C.S.; Links, J.M.; Metcalfe, 
J.; Weyl, H.L.; Kurian, V.; Ernst, M.; London, E.D. Neural systems 
and cue-induced cocaine craving. Neuropsychopharmacology, 
2002, 26, 376-386. 
[79]  Childress, A.R.; Mozley, P.D.; McElgin, W.; Fitzgerald, J.; 
Reivich, M.; O'Brien, C.P. Limbic activation during cue-induced 
cocaine craving. Am. J. Psychiatry, 1999, 156, 11-18. 
[80]  Grant, S.; London, E.D.; Newlin, D.B.; Villemagne, V.L.; Liu, X.; 
Contoreggi, C.; Phillips, R.L.; Kimes, A.S.; Margolin, A. 
Activation of memory circuits during cue-elicited cocaine craving. 
Proc. Natl. Acad. Sci. USA, 1996, 93, 12040-12045. 
[81]  Kilts, C.D. Imaging the roles of the amygdala in drug addiction. 
Psychopharmacol. Bull., 2001, 35, 84-94. 
[82]  Kilts, C.D.; Schweitzer, J.B.; Quinn, C.K.; Gross, R.E.; Faber, 
T.L.; Muhammad, F.; Ely, T.D.; Hoffman, J.M.; Drexler, K.P. 
Neural activity related to drug craving in cocaine addiction. Arch. 
Gen. Psychiatry, 2001, 58, 334-341. 
[83]  Brieter, H.C.; Gollub, R.L.; Weisskoff, R.M.; Kennedy, D.N.; 
Makris, N.; Berke, J.D.; Goodman, J.M.; Kantor, H.L.; Gastfriend, 
D.R.; Riorden, J.P.; Mathew, R.T.; Rosen, B.R.; Hyman, S.E. 
Acute effects of cocaine on human brain activity and emotion. 
Neuron, 1997, 19, 591-611. 
[84]  Wang, Z.; Faith, M.; Patterson, F.; Tang, K.; Kerrin, K.; Wileyto, 
E.P.; Detre, J.A.; Lerman, C. Neural substrates of abstinence-
induced cigarette cravings in chronic smokers. J. Neurosci., 2007, 
27, 14035-14040. 
[85]  Fuchs, R.A.; Evans, K.A.; Ledford, C.C.; Parker, M.P.; Case, J.M.; 
Mehta, R.H.; See, R.E. The role of the dorsomedial prefrontal 
cortex, basolateral amygdala, and dorsal hippocampus in contextual 
reinstatement of cocaine seeking in rats. Neuropsychopharma- 
cology, 2005, 30, 296-309. 
[86]  Ramirez, D.R.; Bell, G.H.; Lasseter, H.C.; Xie, X.; Traina, S.A.; 
Fuchs, R.A. Dorsal hippocampal regulation of memory 
reconsolidation processes that facilitate drug context-induced 
cocaine-seeking behavior in rats. Eur. J. Neurosci., 2009, 30, 901-
912. 
[87]  Fuchs, R.A.; Eaddy, J.L.; Su, Z.I.; Bell, G.H. Interactions of the 
basolateral amygdala with the dorsal hippocampus and dorsomedial 
prefrontal cortex regulate drug context-induced reinstatement of 
cocaine-seeking in rats. Eur. J. Neurosci., 2007, 26, 487-498. 
[88]  Stephenson, F.A. Structure and trafficking of NMDA and GABAA 
receptors. Biochem. Soc. Trans., 2006, 34, 877-881. 
[89]  Paoletti, P.; Neyton, J. NMDA receptor subunits: function and 
pharmacology. Curr. Opin. Pharmacol., 2007, 7, 39-47. 
[90]  Zafra, F.; Aragon, C.; Olivares, L.; Danbolt, N.C.; Gimenez, C.; 
Storm-Mathisen, J. Glycine transporters are differentially expressed 
among CNS cells. J. Neurosci., 1995, 15, 3952-3969. 
[91]  Zafra, F.; Gomeza, J.; Olivares, L.; Aragon, C.; Gimenez, C. 
Regional distribution and developmental variation of the glycine 
transporters GLYT1 and GLYT2 in the rat CNS. Eur. J. Neurosci., 
1995, 7, 1342-1352. 
[92]  Cubelos, B.; Gimenez, C.; Zafra, F. Localization of the GLYT1 
glycine transporter at glutamatergic synapses in the rat brain. 
Cereb. Cortex, 2005, 15, 448-459. 
[93]  Castellano, C.; Cestari, V.; Ciamei, A. NMDA receptors and learning 
and memory processes. Curr. Drug Targets, 2001, 2, 273-283. 
[94]  Perez-Otano, I.; Ehlers, M.D. Homeostatic plasticity and NMDA 
receptor trafficking. Trends Neurosci., 2005, 28, 229-238. 
[95]  Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The 
glutamate receptor ion channels. Pharmacol. Rev., 1999, 51, 7-62. 
[96]  Bliss, T.V.; Collingridge, G.L. A synaptic model of memory: long-
term potentiation in the hippocampus. Nature, 1993, 361, 31-39. 
[97]  Malenka, R.C.; Bear, M.F. LTP and LTD: an embarrassment of 
riches. Neuron, 2004, 44, 5-21. 
[98]  Liu, S.J.; Zukin, R.S. Ca
2+-permeable AMPA receptors in synaptic 
plasticity and neuronal death. Trends Neurosci., 2007, 30, 126-134. 
[99]  Derkach, V.A.; Oh, M.C.; Guire, E.S.; Soderling, T.R. Regulatory 
mechanisms of AMPA receptors in synaptic plasticity. Nat. Rev. 
Neurosci., 2007, 8, 101-113. 
[100]  Bortolotto, Z.A.; Nistico, R.; More, J.C.; Jane, D.E.; Collingridge, 
G.L. Kainate receptors and mossy fiber LTP. Neurotoxicology, 
2005, 26, 769-777. 
[101]  Jane, D.E.; Lodge, D.; Collingridge, G.L. Kainate receptors: 
pharmacology, function and therapeutic potential. Neuropharmacology, 
2009, 56, 90-113. 
[102]  Conn, P.J.; Pin, J.-P. Pharmacology and functions of metabotropic 
glutamate receptors. Annu. Rev. Pharmacol. Toxicol.,  1997,  37, 
205-237. 
[103]  Hermans, E.; Challiss, R.A. Structural, signalling and regulatory 
properties of the group I metabotropic glutamate receptors: 
prototypic family C G-protein-coupled receptors. Biochem. J., 
2001, 359, 465-484. 
[104]  Coutinho, V.; Knopfel, T. Metabotropic glutamate receptors: 
electrical and chemical signaling properties. Neuroscientist, 2002, 
8, 551-561. 
[105]  Conn, P.J.; Lindsley, C.W.; Jones, C.K. Activation of metabotropic 
glutamate receptors as a novel approach for the treatment of 
schizophrenia. Trends. Pharmacol. Sci., 2009, 30, 25-31. 
[106]  Marino, M.J.; Conn, P.J. Direct and indirect modulation of the N-
methyl D-aspartate receptor: potential for the development of novel 
antipsychotic therapies. Curr. Drug Targets CNS Neurol. Disord., 
2002, 1, 1-16. 
[107]  Marino, M.J.; Conn, P.J. Glutamate-based therapeutic approaches: 
allosteric modulators of metabotropic glutamate receptors. Curr. 
Opin. Pharmacol., 2006, 6, 98-102. 
[108]  Ron, D.; Jurd, R. The "ups and downs" of signaling cascades in 
addiction. Sci. STKE, 2005, 2005, re14. 
[109]  Bellone, C.; Luscher, C.; Mameli, M. Mechanisms of synaptic 
depression triggered by metabotropic glutamate receptors. Cell. 
Mol. Life Sci., 2008, 65, 2913-2923. 
[110]  Gladding, C.M.; Fitzjohn, S.M.; Molnar, E. Metabotropic 
glutamate receptor-mediated long-term depression: molecular 
mechanisms. Pharmacol. Rev., 2009, 61, 395-412. 
[111]  Anwyl, R. Metabotropic glutamate receptor-dependent long-term 
potentiation. Neuropharmacology, 2009, 56, 735-740. 406    Current Neuropharmacology, 2010, Vol. 8, No. 4  Cleva et al. 
[112]  Anderson, C.M.; Swanson, R.A. Astrocyte glutamate transport: 
review of properties, regulation, and physiological functions. Glia, 
2000, 32, 1-14. 
[113]  Shigeri, Y.; Seal, R.P.; Shimamoto, K. Molecular pharmacology of 
glutamate transporters, EAATs and VGLUTs. Brain Res. Rev., 
2004, 45, 250-265. 
[114]  Danbolt, N.C. Glutamate uptake. Prog. Neurobiol.,  2001,  65, 1-
105. 
[115]  Melendez, R.I.; Vuthiganon, J.; Kalivas, P.W. Regulation of 
extracellular glutamate in the prefrontal cortex: focus on the cystine 
glutamate exchanger and group I metabotropic glutamate receptors. 
J. Pharmacol. Exp. Ther., 2005, 314, 139-147. 
[116]  McBean, G.J. Cerebral cystine uptake: a tale of two transporters. 
Trends Pharmacol. Sci., 2002, 23, 299-302. 
[117]  Baker, D.A.; Shen, H.; Kalivas, P.W. Cystine/glutamate exchange 
serves as the source for extracellular glutamate: modifications by 
repeated cocaine administration. Amino Acids, 2002, 23, 161-162. 
[118]  Moran, M.M.; McFarland, K.; Melendez, R.I.; Kalivas, P.W.; 
Seamans, J.K. Cystine/glutamate exchange regulates metabotropic 
glutamate receptor presynaptic inhibition of excitatory transmission 
and vulnerability to cocaine seeking. J. Neurosci., 2005, 25, 6389-
6393. 
[119]  Crespo, J.A.; Oliva, J.M.; Ghasemzadeh, M.B.; Kalivas, P.W.; 
Ambrosio, E. Neuroadaptive changes in NMDAR1 gene expression 
after extinction of cocaine self-administration. Ann. N. Y. Acad. 
Sci., 2002, 965, 78-91. 
[120]  Ghasemzadeh, M.B.; Vasudevan, P.; Mueller, C.; Seubert, C.; 
Mantsch, J.R. Region specific alterations in glutamate receptor 
expression and subcellular distribution following extinction of 
cocaine self-administration. Brain Res., 2009, 1267, 89-102. 
[121]  Self, D.W.; Choi, K.H.; Simmons, D.; Walker, J.R.; Smagula, C.S. 
Extinction training regulates neuroadaptive responses to 
withdrawal from chronic cocaine self-administration. Learn. Mem., 
2004, 11, 648-657. 
[122]  Sutton, M.A.; Schmidt, E.F.; Choi, K.-H.; Schad, C.A.; Whisler, 
K.; Simmons, D.; Karanian, D.A.; Monteggia, L.M.; Neve, R.L.; 
Self, D.W. Extinction-induced upregulation in AMPA receptors 
reduces cocaine-seeking behaviour. Nature, 2003, 421, 70-75. 
[123]  Ghasemzadeh, M.B.; Vasudevan, P.; Mueller, C.; Seubert, C.; 
Mantsch, J.R. Neuroadaptations in the cellular and postsynaptic 
group 1 metabotropic glutamate receptor mGluR5 and Homer 
proteins following extinction of cocaine self-administration. 
Neurosci. Lett., 2009, 452, 167-171. 
[124]  Billa, S.K.; Sinha, N.; Rudrabhatla, S.R.; Moron, J.A. Extinction of 
morphine-dependent conditioned behavior is associated with 
increased phosphorylation of the GluR1 subunit of AMPA 
receptors at hippocampal synapses. Eur. J. Neurosci., 2008, 29, 55-
64. 
[125]  Davis, M.; Ressler, K.; Rothbaum, B.O.; Richardson, R. Effects of 
D-cycloserine on extinction: translation from preclinical to clinical 
work. Biol. Psychiatry, 2006, 60, 369-375. 
[126]  Vervliet, B. Learning and memory in conditioned fear extinction: 
effects of d-cycloserine. Acta Psychol. (Amst),  2008,  127, 601- 
613. 
[127]  Thanos, P.K.; Bermeo, C.; Wang, G.J.; Volkow, N.D. D-
Cycloserine accelerates the extinction of cocaine-induced 
conditioned place preference in C57BL/c mice. Behav. Brain Res., 
2009, 199, 345-349. 
[128]  Paolone, G.; Botreau, F.; Stewart, J. The facilitative effects of D-
cycloserine on extinction of a cocaine-induced conditioned place 
preference can be long lasting and resistant to reinstatement. 
Psychopharmacology (Berl), 2008, 202, 403-409. 
[129]  Kelley, J.B.; Anderson, K.L.; Itzhak, Y. Long-term memory of 
cocaine-associated context: disruption and reinstatement. 
Neuroreport, 2007, 18, 777-780. 
[130]  Groblewski, P.A.; Lattal, K.M.; Cunningham, C.L. Effects of D-
cycloserine on extinction and reconditioning of ethanol-seeking 
behavior in mice. Alcohol. Clin. Exp. Res., 2009, 33, 772-782. 
[131]  Vengeliene, V.; Kiefer, F.; Spanagel, R. D-cycloserine facilitates 
the extinction of conditioned alcohol-seeking behaviour in rats. 
Alcohol Alcohol., 2008, 43, 626-629. 
[132]  Shaw, D.; Norwood, K.; Sharp, K.; Quigley, L.; McGovern, S.F.; 
Leslie, J.C. Facilitation of extinction of operant behaviour in mice 
by D-cycloserine. Psychopharmacology (Berl),  2008,  202, 397-
402. 
[133]  Myers, K.M.; Carlezon, W.A., Jr. D-cycloserine facilitates 
extinction of naloxone-induced conditioned place aversion in 
morphine-dependent rats. Biol. Psychiatry, 2010, 67, 85-87. 
[134]  Baker, T.B.; Piper, M.E.; McCarthy, D.E.; Majeskie, M.R.; Fiore, 
M.C. Addiction motivation reformulated: an affective processing 
model of negative reinforcement. Psychol. Rev., 2004, 111, 33-51. 
[135]  Nic Dhonnchadha, B.A.; Szalay, J.J.; Achat-Mendes, C.; Platt, 
D.M.; Otto, M.W.; Spealman, R.D.; Kantak, K.M. D-cycloserine 
deters reacquisition of cocaine self-administration by augmenting 
extinction learning. Neuropsychopharmacology, 2010, 35, 357-367. 
[136]  Kelamangalath, L.; Swant, J.; Stramiello, M.; Wagner, J.J. The 
effects of extinction training in reducing the reinstatement of drug-
seeking behavior: involvement of NMDA receptors. Behav. Brain 
Res., 2007, 185, 119-128. 
[137]  Kelamangalath, L.; Seymour, C.M.; Wagner, J.J. D-serine 
facilitates the effects of extinction to reduce cocaine-primed 
reinstatement of drug-seeking behavior. Neurobiol. Learn. Mem., 
2009, 92, 544-551. 
[138]  Santa Ana, E.J.; Rounsaville, B.J.; Frankforter, T.L.; Nich, C.; 
Babuscio, T.; Poling, J.; Gonsai, K.; Hill, K.P.; Carroll, K.M. D-
Cycloserine attenuates reactivity to smoking cues in nicotine 
dependent smokers: a pilot investigation. Drug Alcohol Depend., 
2009, 104, 220-227. 
[139]  Price, K.L.; McRae-Clark, A.L.; Saladin, M.E.; Maria, M.M.; 
DeSantis, S.M.; Back, S.E.; Brady, K.T. D-cycloserine and cocaine 
cue reactivity: preliminary findings. Am. J. Drug Alcohol Abuse, 
2009, 35, 434-438. 
[140]  Shigemoto, R.; Nomura, S.; Ohishi, H.; Sugihara, H.; Nakanishi, 
S.; Mizuno, N. Immunohistochemical localization of a 
metabotropic glutamate receptor, mGluR5, in the rat brain. 
Neurosci. Lett., 1993, 163, 53-57. 
[141]  Chiamulera, C.; Epping-Jordan, M.P.; Zocchi, A.; Marcon, C.; 
Cottiny, C.; Tacconi, S.; Corsi, M.; Orzi, F.; Conquet, F. 
Reinforcing and locomotor stimulant effects of cocaine are absent 
in mGluR5 null mutant mice. Nat. Neurosci., 2001, 4, 873-874. 
[142]  Kenny, P.J.; Markou, A. The ups and downs of addiction: role of 
metabotropic glutamate receptors. Trends Pharmacol. Sci., 2004, 
25, 265-272. 
[143]  Olive, M.F. mGlu5 receptors: neuroanatomy, pharmacology, and 
role in drug addiction. Curr. Psychiatry Rev., 2005, 1, 197-214. 
[144]  Olive, M.F. Metabotropic glutamate receptor ligands as potential 
therapeutics for drug addiction. Curr. Drug Abuse Rev., 2009, 2, 
83-98. 
[145]  Bird, M.K.; Lawrence, A.J. The promiscuous mGlu5 receptor - a 
range of partners for therapeutic possibilities? Trends Pharmacol. 
Sci., 2009, 30, 617-623. 
[146]  Bird, M.K.; Lawrence, A.J. Group I metabotropic glutamate 
receptors: involvement in drug-seeking and drug-induced plasticity. 
Curr. Mol. Pharmacol., 2009, 2, 83-94. 
[147]  Simonyi, A.; Schachtman, T.R.; Christoffersen, G.R. The role of 
metabotropic glutamate receptor 5 in learning and memory 
processes. Drug News Perspect., 2005, 18, 353-361. 
[148]  Xu, J.; Zhu, Y.; Contractor, A.; Heinemann, S.F. mGluR5 has a 
critical role in inhibitory learning. J. Neurosci.,  2009, 29, 3676-
3684. 
[149]  Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric 
modulators of GPCRs: a novel approach for the treatment of CNS 
disorders. Nat. Rev. Drug Discov., 2009, 8, 41-54. 
[150]  Conn, P.J.; Tamminga, C.; Schoepp, D.D.; Lindsley, C. 
Schizophrenia: moving beyond monoamine antagonists. Mol. 
Interv., 2008, 8, 99-107. 
[151]  Chen, Y.; Conn, P.J. mGluR5 positive allosteric modulators. Drugs 
Fut., 2008, 33, 355-360. 
[152]  O'Brien, J.A.; Lemaire, W.; Chen, T.B.; Chang, R.S.; Jacobson, 
M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; 
Pettibone, D.J.; Conn, P.J.; Williams, D.L., Jr. A family of highly 
selective allosteric modulators of the metabotropic glutamate 
receptor subtype 5. Mol. Pharmacol., 2003, 64, 731-740. 
[153]  O'Brien, J.A.; Lemaire, W.; Wittmann, M.; Jacobson, M.A.; Ha, 
S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J.; Rowe, 
B.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, 
D.L. A novel selective allosteric modulator potentiates the activity 
of native metabotropic glutamate receptor subtype 5 (mGluR5) in 
rat forebrain. J. Pharmacol. Exp. Ther., 2004, 309, 568-577. Glutamatergic Targets for Enhancing Extinction  Current Neuropharmacology, 2010, Vol. 8, No. 4    407 
[154]  Zhao, Z.; Wisnoski, D.D.; O'Brien, J.A.; Lemaire, W.; Williams, 
D.L., Jr.; Jacobson, M.A.; Wittman, M.; Ha, S.N.; Schaffhauser, 
H.; Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, 
G.D.; Lindsley, C.W. Challenges in the development of mGluR5 
positive allosteric modulators: the discovery of CPPHA. Bioorg. 
Med. Chem. Lett., 2007, 17, 1386-1391. 
[155]  de Paulis, T.; Hemstapat, K.; Chen, Y.; Zhang, Y.; Saleh, S.; 
Alagille, D.; Baldwin, R.M.; Tamagnan, G.D.; Conn, P.J. 
Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides 
on positive allosteric modulation of the metabotropic glutamate-5 
receptor in rat cortical astrocytes. J. Med. Chem., 2006, 49, 3332-
3344. 
[156]  Ayala, J.E.; Chen, Y.; Banko, J.L.; Sheffler, D.J.; Williams, R.; 
Telk, A.N.; Watson, N.L.; Xiang, Z.; Zhang, Y.; Jones, P.J.; 
Lindsley, C.W.; Olive, M.F.; Conn, P.J. mGluR5 positive allosteric 
modulators facilitate both hippocampal LTP and LTD and enhance 
spatial learning. Neuropsychopharmacology, 2009, 34, 2057-2071. 
[157]  Balschun, D.; Zuschratter, W.; Wetzel, W. Allosteric enhancement 
of metabotropic glutamate receptor 5 function promotes spatial 
memory. Neuroscience, 2006, 142, 691-702. 
[158]  Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O'Brien J, A.; 
Lemaire, W.; Williams, D.L., Jr.; Burno, M.; Sur, C.; Kinney, 
G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Duggan, M.E.; 
Hartman, G.D.; Conn, P.J.; Huff, J.R. Discovery of positive 
allosteric modulators for the metabotropic glutamate receptor 
subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamides that potentiate receptor function in vivo.  J. Med. 
Chem., 2004, 47, 5825-5828. 
[159]  Kinney, G.G.; O'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J.; 
Clements, M.K.; Chen, T.B.; Wisnoski, D.D.; Lindsley, C.W.; 
Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; 
Pettibone, D.J.; Conn, P.J.; Williams, D.L., Jr. A novel selective 
positive allosteric modulator of metabotropic glutamate receptor 
subtype 5 has in vivo activity and antipsychotic-like effects in rat 
behavioral models. J. Pharmacol. Exp. Ther., 2005, 313, 199-206. 
[160]  Homayoun, H.; Moghaddam, B. Orbitofrontal cortex neurons as a 
common target for classic and glutamatergic antipsychotic drugs. 
Proc. Natl. Acad. Sci. USA, 2008, 105, 18041-18046. 
[161]  Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; 
Atkinson, P.J.; Wantuch, C.; Popiolek, M.; Day, M.; Khawaja, X.; 
Smith, D.; Olsen, M.; Kouranova, E.; Gilbert, A.; Lai, M.; Pausch, 
M.H.; Pruthi, F.; Pulicicchio, C.; Brandon, N.J.; Comery, T.A.; 
Beyer, C.E.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K.L. 
ADX47273: a novel metabotropic glutamate receptor 5 selective 
positive allosteric modulator with preclinical antipsychotic-like and 
pro-cognitive activities. J. Pharmacol. Exp. Ther., 2008, 327, 827-
839. 
[162]  Schlumberger, C.; Pietraszek, M.; Gravius, A.; Klein, K.U.; Greco, 
S.; More, L.; Danysz, W. Comparison of the mGlu5 receptor 
positive allosteric modulator ADX47273 and the mGlu2/3 receptor 
agonist LY354740 in tests for antipsychotic-like activity. Eur. J. 
Pharmacol., 2009, 623, 73-83. 
[163]  Uslaner, J.M.; Parmentier-Batteur, S.; Flick, R.B.; Surles, N.O.; 
Lam, J.S.; McNaughton, C.H.; Jacobson, M.A.; Hutson, P.H. Dose-
dependent effect of CDPPB, the mGluR5 positive allosteric 
modulator, on recognition memory is associated with GluR1 and 
CREB phosphorylation in the prefrontal cortex and hippocampus. 
Neuropharmacology, 2009, 57, 531-538. 
[164]  Gass, J.T.; Olive, M.F. Positive allosteric modulation of mGluR5 
receptors facilitates extinction of a cocaine contextual memory. 
Biol. Psychiatry, 2009, 65, 717-720. 
[165]  Olive, M.F.; Wischerath, K.C.; Cleva, R.M.; Gass, J.T. Positive 
allosteric modulation of mGluR5 receptors decreases extinction 
responding following intravenous heroin and cocaine self-
administration: Correlation with hippocampal neurogenesis. Society 
for Neuroscience Meeting Planner, Chicago, IL, 2009,  Program 
No. 348.11. Online. 
[166]  Gomeza, J.; Ohno, K.; Betz, H. Glycine transporter isoforms in   
the mammalian central nervous system: structures, functions   
and therapeutic promises. Curr. Opin. Drug Discov. Dev., 2003, 6, 
675-682. 
[167]  Sur, C.; Kinney, G.G. Glycine transporter 1 inhibitors and 
modulation of NMDA receptor-mediated excitatory neurotrans- 
mission. Curr. Drug Targets, 2007, 8, 643-649. 
[168]  Sur, C.; Kinney, G.G. The therapeutic potential of glycine 
transporter-1 inhibitors. Expert. Opin. Investig. Drugs,  2004,  13, 
515-521. 
[169]  Yang, C.R.; Svensson, K.A. Allosteric modulation of NMDA 
receptor via elevation of brain glycine and D-serine: the therapeutic 
potentials for schizophrenia. Pharmacol. Ther.,  2008,  120, 317-
332. 
[170]  Betz, H.; Gomeza, J.; Armsen, W.; Scholze, P.; Eulenburg, V. 
Glycine transporters: essential regulators of synaptic transmission. 
Biochem. Soc. Trans., 2006, 34, 55-58. 
[171]  Aubrey, K.R.; Vandenberg, R.J. N[3-(4'-fluorophenyl)-3-(4'-
phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent 
inhibitor of glycine transport. Br. J. Pharmacol., 2001, 134, 1429-
1436. 
[172]  Walker, G.B.; Hamilton, W.; Ge, J.; Bruin, J.; Shahid, M.; Hill, D. 
ORG 25935: a selective glycine uptake inhibitor. Schizophrenia 
Res., 2001, 49 (Suppl 1), 97. 
[173]  Wolkenberg, S.E.; Zhao, Z.; Wisnoski, D.D.; Leister, W.H.; 
O'Brien, J.; Lemaire, W.; Williams, D.L., Jr.; Jacobson, M.A.; Sur, 
C.; Kinney, G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Gibson, 
C.; Ma, B.K.; Polsky-Fisher, S.L.; Lindsley, C.W.; Hartman, G.D. 
Discovery of GlyT1 inhibitors with improved pharmacokinetic 
properties. Bioorg. Med. Chem. Lett., 2009, 19, 1492-1495. 
[174]  Zhao, Z.; Leister, W.H.; O'Brien, J.A.; Lemaire, W.; Williams, 
D.L., Jr.; Jacobson, M.A.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; 
Tiller, P.R.; Smith, S.; Hartman, G.D.; Lindsley, C.W.; 
Wolkenberg, S.E. Discovery of N-{[1-(propylsulfonyl)-4-pyridin-
2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and 
potent GlyT1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1488-
1491. 
[175]  Perry, K.W.; Falcone, J.F.; Fell, M.J.; Ryder, J.W.; Yu, H.; Love, 
P.L.; Katner, J.; Gordon, K.D.; Wade, M.R.; Man, T.; Nomikos, 
G.G.; Phebus, L.A.; Cauvin, A.J.; Johnson, K.W.; Jones, C.K.; 
Hoffmann, B.J.; Sandusky, G.E.; Walter, M.W.; Porter, W.J.; 
Yang, L.; Merchant, K.M.; Shannon, H.E.; Svensson, K.A. 
Neurochemical and behavioral profiling of the selective GlyT1 
inhibitors ALX5407 and LY2365109 indicate a preferential action 
in caudal vs. cortical brain areas. Neuropharmacology, 2008, 55, 
743-754. 
[176]  Depoortere, R.; Dargazanli, G.; Estenne-Bouhtou, G.; Coste, A.; 
Lanneau, C.; Desvignes, C.; Poncelet, M.; Heaulme, M.; Santucci, 
V.; Decobert, M.; Cudennec, A.; Voltz, C.; Boulay, D.; Terranova, 
J.P.; Stemmelin, J.; Roger, P.; Marabout, B.; Sevrin, M.; Vige, X.; 
Biton, B.; Steinberg, R.; Francon, D.; Alonso, R.; Avenet, P.; Oury-
Donat, F.; Perrault, G.; Griebel, G.; George, P.; Soubrie, P.; 
Scatton, B. Neurochemical, electrophysiological and 
pharmacological profiles of the selective inhibitor of the glycine 
transporter-1 SSR504734, a potential new type of antipsychotic. 
Neuropsychopharmacology, 2005, 30, 1963-1985. 
[177]  Yee, B.K.; Balic, E.; Singer, P.; Schwerdel, C.; Grampp, T.; 
Gabernet, L.; Knuesel, I.; Benke, D.; Feldon, J.; Mohler, H.; 
Boison, D. Disruption of glycine transporter 1 restricted to 
forebrain neurons is associated with a procognitive and 
antipsychotic phenotypic profile. J. Neurosci.,  2006,  26, 3169-
3181. 
[178]  Singer, P.; Feldon, J.; Yee, B.K. The glycine transporter 1 inhibitor 
SSR504734 enhances working memory performance in a 
continuous delayed alternation task in C57BL/6 mice. Psychophar- 
macology (Berl), 2009, 202, 371-384. 
[179]  Singer, P.; Boison, D.; Mohler, H.; Feldon, J.; Yee, B.K. Enhanced 
recognition memory following glycine transporter 1 deletion in 
forebrain neurons. Behav. Neurosci., 2007, 121, 815-825. 
[180]  Singer, P.; Boison, D.; Mohler, H.; Feldon, J.; Yee, B.K. Deletion 
of glycine transporter 1 (GlyT1) in forebrain neurons facilitates 
reversal learning: enhanced cognitive adaptability? Behav. 
Neurosci., 2009, 123, 1012-1027. 
[181]  Tsai, G.; Ralph-Williams, R.J.; Martina, M.; Bergeron, R.; Berger-
Sweeney, J.; Dunham, K.S.; Jiang, Z.; Caine, S.B.; Coyle, J.T. 
Gene knockout of glycine transporter 1: characterization of the 
behavioral phenotype. Proc. Natl. Acad. Sci. USA,  2004,  101, 
8485-8490. 
[182]  Uslaner, J.M.; Drott, J.T.; Sharik, S.S.; Theberge, C.R.; Sur, C.; 
Zeng, Z.; Williams, D.L.; Hutson, P.H. Inhibition of glycine 
transporter 1 attenuates nicotine- but not food-induced cue-408    Current Neuropharmacology, 2010, Vol. 8, No. 4  Cleva et al. 
potentiated reinstatement for a response previously paired with 
sucrose. Behav. Brain Res., 2010, 207, 37-43. 
[183]  Mao, S.C.; Lin, H.C.; Gean, P.W. Augmentation of fear extinction 
by infusion of glycine transporter blockers into the amygdala. Mol. 
Pharmacol., 2009, 76, 369-378. 
[184]  Arai, A.C.; Kessler, M. Pharmacology of ampakine modulators: 
from AMPA receptors to synapses and behavior. Curr. Drug 
Targets, 2007, 8, 583-602. 
[185]  Morrow, J.A.; Maclean, J.K.; Jamieson, C. Recent advances in 
positive allosteric modulators of the AMPA receptor. Curr. Opin. 
Drug Discov. Dev., 2006, 9, 571-579. 
[186]  Sekiguchi, M.; Fleck, M.W.; Mayer, M.L.; Takeo, J.; Chiba,   
Y.; Yamashita, S.; Wada, K. A novel allosteric potentiator of 
AMPA receptors: 4--2-(phenylsulfonylamino)ethylthio--2,6-difluoro-
phenoxyaceta mide. J. Neurosci., 1997, 17, 5760-5771. 
[187]  Danysz, W. CX-516 Cortex pharmaceuticals. Curr. Opin. Investig. 
Drugs, 2002, 3, 1081-1088. 
[188]  Woolley, M.L.; Waters, K.A.; Gartlon, J.E.; Lacroix, L.P.; 
Jennings, C.; Shaughnessy, F.; Ong, A.; Pemberton, D.J.; Harries, 
M.H.; Southam, E.; Jones, D.N.; Dawson, L.A. Evaluation of the 
pro-cognitive effects of the AMPA receptor positive modulator, 5-
(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. 
Psychopharmacology (Berl), 2009, 202, 343-354. 
[189]  Zivkovic, I.; Thompson, D.M.; Bertolino, M.; Uzunov, D.; DiBella, 
M.; Costa, E.; Guidotti, A. 7-Chloro-3-methyl-3-4-dihydro-2H-
1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine 
derivative that enhances cognition by attenuating DL-alpha-amino-
2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) 
receptor desensitization. J. Pharmacol. Exp. Ther., 1995, 272, 300-
309. 
[190]  Yamada, D.; Zushida, K.; Wada, K.; Sekiguchi, M. Pharma- 
cological discrimination of extinction and reconsolidation of 
contextual fear memory by a potentiator of AMPA receptors. 
Neuropsychopharmacology, 2009, 34, 2574-2584. 
[191]  Zushida, K.; Sakurai, M.; Wada, K.; Sekiguchi, M. Facilitation of 
extinction learning for contextual fear memory by PEPA: a 
potentiator of AMPA receptors. J. Neurosci., 2007, 27, 158-166. 
[192]  LaLumiere, R.T.; Niehoff, K.E.; Kalivas, P.W. The infralimbic 
cortex regulates the consolidation of extinction after cocaine self-
administration. Learn. Mem., 2010, 17, 168-175. 
[193]  Baker, D.A.; McFarland, K.; Lake, R.W.; Shen, H.; Tang, X.C.; 
Toda, S.; Kalivas, P.W. Neuroadaptations in cystine-glutamate 
exchange underlie cocaine relapse. Nat. Neurosci., 2003, 6, 743-749. 
[194]  Madayag, A.; Lobner, D.; Kau, K.S.; Mantsch, J.R.; Abdulhameed, 
O.; Hearing, M.; Grier, M.D.; Baker, D.A. Repeated N-
acetylcysteine administration alters plasticity-dependent effects of 
cocaine. J. Neurosci., 2007, 27, 13968-13976. 
[195]  Moussawi, K.; Pacchioni, A.; Moran, M.; Olive, M.F.; Gass, J.T.; 
Lavin, A.; Kalivas, P.W. N-Acetylcysteine reverses cocaine-
induced metaplasticity. Nat. Neurosci., 2009, 12, 182-189. 
[196]  Kau, K.S.; Madayag, A.; Mantsch, J.R.; Grier, M.D.; Abdulhameed, 
O.; Baker, D.A. Blunted cystine-glutamate antiporter function in 
the nucleus accumbens promotes cocaine-induced drug seeking. 
Neuroscience, 2008, 155, 530-537. 
[197]  LaRowe, S.D.; Mardikian, P.; Malcolm, R.; Myrick, H.; Kalivas, 
P.W.; McFarland, K.; Saladin, M.; McRae, A.; Brady, K. Safety 
and tolerability of N-acetylcysteine in cocaine-dependent 
individuals. Am. J. Addict., 2006, 15, 105-110. 
[198]  LaRowe, S.D.; Myrick, H.; Hedden, S.; Mardikian, P.; Saladin, M.; 
McRae, A.; Brady, K.; Kalivas, P.W.; Malcolm, R. Is cocaine 
desire reduced by N-acetylcysteine? Am. J. Psychiatry, 2007, 164, 
1115-1117. 
[199]  Knackstedt, L.A.; Larowe, S.; Mardikian, P.; Malcolm, R.; 
Upadhyaya, H.; Hedden, S.; Markou, A.; Kalivas, P.W. The role of 
cystine-glutamate exchange in nicotine dependence in rats and 
humans. Biol. Psychiatry, 2009, 65, 841-845. 
[200]  Zhou, W.; Kalivas, P.W. N-Acetylcysteine reduces extinction 
responding and induces enduring reductions in cue- and heroin-
induced drug-seeking. Biol. Psychiatry, 2008, 63, 338-340. 
[201]  LaRowe, S.D.; Kalivas, P.W. The role of N-acetylcysteine in 
inhibiting responding during extinction in rats trained to self-
administer cocaine. Open Addict. J., 2010, 3, 88-91. 
[202]  Sofuoglu, M. Cognitive enhancement as a pharmacotherapy target 
for stimulant addiction. Addiction, 2010, 105, 38-48. 
 
 
Received: December 31, 2009  Revised: May 11, 2010  Accepted: May 26, 2010 
 
 